Showing 4411-4420 of 5627 results for "".
- Oculis Announces Positive Data From Two Proof-of-Concept Phase 2 Trials With OCS-02 in Dry Eye Disease and Acute Anterior Uveitishttps://modernod.com/news/oculis-announces-positive-data-from-two-proof-of-concept-phase-2-trials-with-ocs-02-in-dry-eye-disease-and-acute-anterior-uveitis/2479192/Oculis announced positive data from two clinical proof of concept phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in dry eye disease (DED) and acute anterior uveitis (AAU). The data were presented for the first time at ARVO 2021, the annual meeting of th
- New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced AMD Progressionhttps://modernod.com/news/new-national-eye-institute-data-shows-areds2-nutrient-formula-continues-to-reduce-the-risk-of-moderate-to-advanced-amd-progression/2479193/Bausch + Lomb announced new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study. Based on this data, the NEI continues to recommend a specific nutrient formula to help
- Zeiss Celebrates 175th Anniversary in 2021https://modernod.com/news/zeiss-celebrates-175th-anniversary-in-2021/2479194/Zeiss’ success story began 175 years ago, in a small workshop. On November 17, 1846, young mechanic Carl Zeiss opened his workshop for precision mechanics and optics in Jena, thus laying the foundation for what would become today’s global technology player Zeiss. Zeiss went on to join
- Innovega’s eMacula System Shows Potential to Increase Independence for Visually Impairedhttps://modernod.com/news/innovegas-emacula-system-shows-potential-to-increase-independence-for-visually-impaired/2479190/The use of Innovega eMacula system, which pairs smart contact lenses with display eyewear, demonstrated positive results with partially sighted subjects for their daily tasks, including reading, smart phone use, and distance vision, according to research conducted at The Ohio
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Sinopharm’s COVID-19 Vaccine Granted WHO Emergency Listinghttps://modernod.com/news/sinopharms-covid-19-vaccine-granted-who-emergency-listing/2479184/The World Health Organization (WHO) on Friday approved Sinopharm’s COVID-19 vaccine for emergency use, paving the way for millions more doses to be included into the COVAX program in the coming weeks or months for rollout in developing countries, according to a FirstWord report. The decisio
- Clearside Biomedical Announces Multiple Poster Presentations at ARVOhttps://modernod.com/news/clearside-biomedical-announces-multiple-poster-presentations-at-arvo/2479185/Clearside Biomedical announced that multiple clinical poster presentations related to its suprachoroidal injection platform and programs were delivered at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting which took place May 1-7, 2021.
- New Partnership Expands Alcon’s In-Office Dry Eye and Ocular Health Portfoliohttps://modernod.com/news/new-partnership-expands-alcons-in-office-dry-eye-and-ocular-health-portfolio/2479180/Alcon has gained exclusive rights to sell the technology and accompanying products of BlephEx, a provider of bacterial biofilm theory, in the United States effective May 1, 2021. Terms of the deal were not disclosed. The BlephEx eyelid cleaning device and LashCam iR WIFI
- LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-presents-valeda-treatment-benefits-for-photobiomodulation-in-early-patients-with-diabetic-retinopathy-and-macular-edema/2479177/LumiThera announced research investigators presented positive clinical findings following PBM treatment with the Valeda Light Delivery System from an ongoing safety and efficacy study in early diabetic retinopathy (DR) patients with central macular edema (DME) at the Association for Research in V
- Johnson & Johnson Vision Announces FDA Approval Of Tecnis Synergy And Tecnis Synergy Toric II IOLs In the UShttps://modernod.com/news/johnson-johnson-vision-announces-the-approval-of-tecnis-synergy-and-tecnis-synergy-toric-ii-iols-in-the-us/2479178/Johnson & Johnson Vision announced the FDA approval of Tecnis Synergy and Tecnis Synergy Toric II IOLs, and the Health Canada approval of Tecnis Synergy Toric II IOLs. This next-generation PCIOL is built on the legacy Tecnis platform and delivers a wide range of continuous vision with